Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
-
-
brenda
-
prepared from forebrain of 1-day old Swiss Webster mice
brenda
-
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
-
brenda
primary hepatic amd gill epithelial cells
brenda
-
recombinant enzymes expressed in insect cells
brenda
-
brenda
-
brenda
-
brenda
-
-
brenda
-
-
brenda
-
brenda
-
-
brenda
-
brenda
-
brenda
-
-
brenda
-
brenda
FMO1, expression profiling in tissue from patients with atrial fibrillation
brenda
-
brenda
-
-
brenda
-
brenda
-
brenda
-
brenda
-
brenda
-
brenda
-
brenda
-
-
brenda
reduced expression in amyotrophic lateral sclerosis
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
brenda
-
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
brenda
-
brenda
-
-
-
brenda
-
-
brenda
-
brenda
-
brenda
-
brenda
-
-
brenda
-
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
brenda
-
brenda
adult and fetal, high expression level of FMO1
brenda
expression of the FMO1 gene is not silenced postnatally in kidney
brenda
-
FMO1 is expressed primarily in the kidney and the fetal liver
brenda
no expression of FMO1, but of FMO4
brenda
-
isoform FMO1
brenda
KC734478, KC734481, KC734482, KC734486
most abundantly expressed
brenda
-
-
brenda
expression of the FMO1 gene is not silenced postnatally in liver and kidney
brenda
-
isoforms FMO1 and FMO5
brenda
-
-
-
brenda
-
-
brenda
-
-
brenda
-
brenda
FMO1 shows low expression
brenda
FMO3 is expressed in the renal collecting tubules, in renal medulla, and in renal glomerulus
brenda
FMO4 is expressed in the renal collecting tubules, in renal medulla, and in renal glomerulus
brenda
-
-
brenda
rosette leaf
brenda
-
in three-week-old Polygonum tinctorium specimens, the first leaves demonstrate higher levels of PtFMO expression than the subsequent leaves
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
-
brenda
-
-
348504, 348508, 348510, 348512, 658461, 659823, 671729, 673286, 673290, 676116, 686355, 686357, 703411, 706824 brenda
-
brenda
-
-
brenda
-
brenda
-
brenda
-
brenda
-
-
brenda
-
brenda
-
-
brenda
-
brenda
-
brenda
fetal and adult
brenda
adult and fetal
brenda
-
male and female
brenda
-
FMO3 is the major FMO
brenda
adult liver
brenda
-
isozyme FMO3
brenda
-
low level of tamoxifen N-oxide production in human liver microsomes may be explained by the kinetics of FMO1 versus FMO3, isozyme expression pattern, overview, fetal liver expresses only isozyme FMO1
brenda
birth is necessary but not sufficient for FMO3 onset in the liver, it occurs between week 3 and 10 after birth
brenda
expression of the FMO1 gene is silenced postnatally in liver
brenda
high level expression in adult liver
brenda
-
FMO1 is expressed primarily in the kidney and the fetal liver
brenda
-
FMO1 is the major isozyme in liver
brenda
no expression of FMO1, but of FMO4
brenda
-
FMO3 and FMO5 are the predominant FMO forms in adult liver
brenda
in human fetal liver, the major isozyme is FMO1
brenda
-
isoforms FMO3 and FMO5
brenda
human FMO3 protein is predominantly expressed in the liver
brenda
-
-
brenda
KC734478, KC734481, KC734482, KC734486
most abundantly expressed
brenda
-
-
brenda
-
-
brenda
-
brenda
-
-
brenda
-
brenda
-
brenda
-
brenda
-
predominantly
brenda
-
expression analysis of FMO3 in liver and after treatment with conjugated linoleic acid isomers
brenda
expression of the FMO1 gene is not silenced postnatally in liver and kidney
brenda
-
FMO1, FMO3, and FMO5
brenda
-
isoforms FMO1, FMO3 and FMO5
brenda
-
predominantly
-
brenda
-
-
-
brenda
-
-
-
brenda
-
-
brenda
-
brenda
-
-
brenda
-
isozyme FMO3
brenda
-
-
brenda
-
brenda
-
FMO1 is the major isozyme in liver
brenda
FMO4 occurs in lobular distribution
brenda
highest expression of FMO1 in the perivenous region
brenda
highest expression of FMO3 in the perivenous region
brenda
-
-
348485, 348486, 348487, 348488, 348490, 348491, 348492, 348494, 348497, 348498, 348500, 348505, 348507, 659828, 673313, 703320, 712902 brenda
-
isozyme FMO1
brenda
-
FMO activity is substantial in the liver microsomes of one-day-old neonatal pigs. This activity increases rapidly in 2 weeks of growth and then remains high. The highest porcine hepatic FMO activity is detected at the age of 20 weeks. Since both liver and body weight increase during the growth of pigs, the growth impact on the hepatic FMO activity is also assessed using in vivo intrinsic clearance of benzydamine N-oxidation at different ages. Although the highest in vivo intrinsic clearance is still at around 2-5 weeks age, the clearance is reduced at age of 20 weeks obviously
brenda
-
-
brenda
-
-
brenda
-
brenda
-
-
brenda
-
brenda
-
isozyme FMO2
brenda
-
low expression of isozyme FMO2
brenda
FMO2 mainly
brenda
isozyme FMO2 is expressed at high levels in lung
brenda
-
isoform FMO2
brenda
-
-
brenda
-
brenda
-
high expression of isozyme FMO2
brenda
-
isoforms FMO1 and FMO2
brenda
-
-
-
brenda
-
-
brenda
-
lung isozyme FMO2
brenda
-
-
brenda
-
high expression of isozyme FMO2
brenda
-
high expression of isozyme FMO2
brenda
-
-
brenda
-
brenda
-
-
brenda
-
brenda
additional information
-
differential expression of isozymes in tissues
brenda
additional information
broad tissue distribution, overview
brenda
additional information
broad tissue distribution, overview
brenda
additional information
broad tissue distribution, overview
brenda
additional information
broad tissue distribution, overview
brenda
additional information
broad tissue distribution, overview
brenda
additional information
no expression of FMO3 in Hep-G2 cells, decreased hepatic nuclear factor HNF4alpha levels and DNA hypermethylation are the mechanisms suppressing Hep-G2 FMO3 expression
brenda
additional information
-
no expression of FMO3 in Hep-G2 cells, decreased hepatic nuclear factor HNF4alpha levels and DNA hypermethylation are the mechanisms suppressing Hep-G2 FMO3 expression
brenda
additional information
tissue-specific and devlopmental expression of FMO3, overview
brenda
additional information
tissue-specific and devlopmental expression of FMO3, overview
brenda
additional information
tissue-specific and devlopmental expression of FMO3, overview
brenda
additional information
tissue-specific and devlopmental expression of FMO3, overview
brenda
additional information
tissue-specific and devlopmental expression of FMO3, overview
brenda
additional information
tissue-specific expression of FMO1, overview
brenda
additional information
tissue-specific expression of FMO1, overview
brenda
additional information
tissue-specific expression of FMO1, overview
brenda
additional information
tissue-specific expression of FMO1, overview
brenda
additional information
tissue-specific expression of FMO1, overview
brenda
additional information
tissue-specific expression of FMO2, overview
brenda
additional information
tissue-specific expression of FMO2, overview
brenda
additional information
tissue-specific expression of FMO2, overview
brenda
additional information
tissue-specific expression of FMO2, overview
brenda
additional information
tissue-specific expression of FMO2, overview
brenda
additional information
tissue-specific expression of FMO5, overview, the enzyme is increased in ERalpha-positive tumors
brenda
additional information
tissue-specific expression of FMO5, overview, the enzyme is increased in ERalpha-positive tumors
brenda
additional information
tissue-specific expression of FMO5, overview, the enzyme is increased in ERalpha-positive tumors
brenda
additional information
tissue-specific expression of FMO5, overview, the enzyme is increased in ERalpha-positive tumors
brenda
additional information
tissue-specific expression of FMO5, overview, the enzyme is increased in ERalpha-positive tumors
brenda
additional information
-
specific isozyme localization patterns, overview
brenda
additional information
specific isozyme localization patterns, overview
brenda
additional information
-
recombinant FMO1
brenda
additional information
no activity in fetal human liver, intestine, and kidney
brenda
additional information
-
no activity in fetal human liver, intestine, and kidney
brenda
additional information
-
not activity in brain A
brenda
additional information
-
tissue-specific expression of FMO isozymes, quantitative expression analysis, overview
brenda
additional information
-
specific isozyme localization patterns, overview
brenda
additional information
-
not activity in brain A
-
brenda
additional information
-
differential expression of isozymes in tissues
brenda
additional information
-
the lung isozyme FMO2 is distinct from the liver isozyme in having high activity toward primary alkyl amines, restricted substrate specificity related to steric properties, resistance to detergent inhibition and enhanced thermal stability
brenda
additional information
-
differential expression of isozymes in tissues
brenda